Latest News on AVIR

Financial News Based On Company


Advertisement
Advertisement

Form 4 Atea Pharmaceuticals Inc: Bruce Polsky (Director) For: 19 November By Investing.com

https://za.investing.com/news/stock-market-news/form-4-atea-pharmaceuticalsinc-bruce-polsky-director-for-19-november-93CH-4587726
This article reports on a Form 4 filing for Atea Pharmaceuticals Inc., indicating a transaction by Director Bruce Polsky on November 19. Form 4 filings provide information on changes in beneficial ownership of a company's securities by insiders. The article also lists the stock symbol AVIR, which saw a -0.64% change.

Atea Pharmaceuticals director Bruno Lucidi sells $116,410 in stock

https://www.investing.com/news/insider-trading-news/atea-pharmaceuticals-director-bruno-lucidi-sells-116410-in-stock-93CH-5040562
Bruno Lucidi, a director at Atea Pharmaceuticals (NASDAQ:AVIR), sold shares worth $116,410 in November 2026 after acquiring them through stock option exercises. The sales were conducted to cover the exercise price of the options and for tax planning purposes. Despite the sales, InvestingPro analysis suggests Atea Pharmaceuticals is undervalued, with a fair value of $4.36, and the company recently reported a smaller-than-expected loss for Q3.

Form 4 Atea Pharmaceuticals Inc: Bruno Lucidi (Director) For: 17 November

https://uk.investing.com/news/stock-market-news/form-4-atea-pharmaceuticalsinc-bruno-lucidi-director-for-17-november-93CH-4994832
This article reports on a Form 4 filing for Atea Pharmaceuticals Inc., indicating that Bruno Lucidi, a director, made a transaction on November 17. The filing was published on November 20, 2026, and is a standard disclosure of insider trading activity. No specific details about the transaction value or type are provided in this brief announcement.

Atea Pharmaceuticals Director Bruce Polsky Sells 8,750 Shares at $4.03 Each

https://kalkinemedia.com/us/news/announcements/atea-pharmaceuticals-director-bruce-polsky-sells-8750-shares-at-403-each
Bruce Polsky, a Director at Atea Pharmaceuticals, Inc. (NASDAQ:AVIR), sold 8,750 shares of common stock on November 19, 2026, at a weighted average price of $4.0341 per share. The transaction, disclosed in a Form 4 filing, was conducted to cover option exercise costs and for tax planning purposes. Following the sale, Polsky directly owns 149,830 common shares in the company.

Form 4 Atea Pharmaceuticals Inc: Bruce Polsky (Director) For: 19 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-atea-pharmaceuticalsinc-bruce-polsky-director-for-19-november-93CH-5716693
This article reports on a Form 4 filing for Atea Pharmaceuticals Inc, indicating an insider transaction by Director Bruce Polsky on November 19. The brief report highlights the filing related to the company, also noting its stock symbol AVIR.
Advertisement

After selling 8,750 shares, Atea Pharmaceuticals (AVIR) director Bruce Polsky directly held 149,830.

https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-7da1e92108b8.html
Atea Pharmaceuticals director Bruce Polsky sold 8,750 shares of common stock on November 19, 2026, at a weighted-average price of $4.0341 per share. These sales were made in multiple transactions ranging from $4.00 to $4.04 and were for tax planning purposes and to pay options' exercise price. Following the sale, Polsky directly held 149,830 shares of the company.

On Nov. 19, an Atea Pharmaceuticals (AVIR) director exercised options at $1.24 a share and sold 22,619 shares.

https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-c3697da8a088.html
Atea Pharmaceuticals (AVIR) director Bruno Lucidi engaged in insider transactions, exercising options to acquire shares and subsequently selling a portion. On November 17, 2026, he exercised options for 21,628 shares at $1.24 and sold 6,741 shares at $4.0335. Two days later, on November 19, 2026, Lucidi exercised options for an additional 53,372 shares at $1.24 and sold 22,619 shares at $3.9445, reporting these sales to cover exercise costs and for tax-planning purposes.

After exercising stock options, Atea Pharmaceuticals (AVIR) director Bruno Lucidi proposes selling 22,619 shares.

https://www.stocktitan.net/sec-filings/AVIR/144-atea-pharmaceuticals-inc-sec-filing-a173832bb0f5.html
Atea Pharmaceuticals director Bruno Lucidi has proposed selling 22,619 common shares with an aggregate market value of $89,219.37, following an acquisition through a stock option exercise on November 19, 2026. The filing also reports a prior sale of 6,741 common shares on November 17, 2026, for gross proceeds of $27,189.82. Morgan Stanley Smith Barney LLC is named as the broker for the proposed transaction.

Form 144 ATEA PHARMACEUTICALS For: 19 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-atea-pharmaceuticals-for-19-november-93CH-4968696
Investing.com reported on a Form 144 filing for ATEA Pharmaceuticals on November 19, 2026. This type of filing indicates an intent to sell restricted or controlled securities. The article, part of a "Stock Market" update, provides this brief notice without further details on the transaction.

Form 4 Atea Pharmaceuticals Inc: Bruce Polsky (Director) For: 16 November By Investing.com

https://in.investing.com/news/stock-market-news/form-4-atea-pharmaceuticalsinc-bruce-polsky-director-for-16-november-93CH-5713999
The article reports that Bruce Polsky, a Director at Atea Pharmaceuticals Inc., filed a Form 4. This financial disclosure pertains to transactions made on November 16. The brief notice was published on Investing.com.
Advertisement

Bruce Polsky exercised 75,000 options at Atea Pharmaceuticals (AVIR) and sold 41,226 shares.

https://www.stocktitan.net/sec-filings/AVIR/form-4-atea-pharmaceuticals-inc-insider-trading-activity-89321102adc2.html
Atea Pharmaceuticals director Bruce Polsky exercised 75,000 stock options at $1.24 per share between November 16-18, 2026. He subsequently sold 41,226 shares across those dates at weighted average prices ranging from $3.9502 to $4.2683, primarily for tax-planning purposes and to cover the exercise price. The transactions were reported in an SEC Form 4 filing.

Bruce Polsky proposes selling 18,252 Atea Pharmaceuticals (AVIR) shares acquired by exercising options.

https://www.stocktitan.net/sec-filings/AVIR/144-atea-pharmaceuticals-inc-sec-filing-560c6b86c09a.html
Atea Pharmaceuticals (AVIR) director Bruce Polsky has filed a Form 144 notice proposing the sale of 18,252 common shares, valued at $72,099.05, with an approximate sale date of November 18, 2026. These shares were acquired on the same day through a stock option exercise paid in cash. The filing also details prior sales by Polsky on November 16 and 17, 2026.

Form 144 ATEA PHARMACEUTICALS For: 18 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-atea-pharmaceuticals-for-18-november-93CH-4966711
This article announces the filing of Form 144 for Atea Pharmaceuticals on November 18. It is a brief notification from Investing.com, providing basic information without further details on the transaction. The content also includes extensive market data and related news.

Director Bruce Polsky plans to sell 8,720 Atea Pharmaceuticals (AVIR) shares after exercising options.

https://www.stocktitan.net/sec-filings/AVIR/144-atea-pharmaceuticals-inc-sec-filing-410a89a711ff.html
Atea Pharmaceuticals director Bruce Polsky has filed a Form 144 notice to sell 8,720 common shares with an aggregate market value of $35,155.55, with an approximate sale date of November 17, 2026. These shares were acquired through a stock option exercise on the same date. The filing also reports that Polsky sold 14,254 common shares on November 16, 2026, for gross proceeds of $60,840.35 during the preceding three months.

Form 144 ATEA PHARMACEUTICALS For: 17 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-atea-pharmaceuticals-for-17-november-93CH-4965143
This article announces the filing of Form 144 for ATEA PHARMACEUTICALS on November 17, 2026. Form 144 is a notice of the intent to sell restricted securities. The brief notice highlights the company's stock symbol AVIR and its performance on the day.
Advertisement

A proposed sale of 6,741 Atea Pharmaceuticals (AVIR) shares comes from director Bruno Lucidi.

https://www.stocktitan.net/sec-filings/AVIR/144-atea-pharmaceuticals-inc-sec-filing-0d4cce570145.html
Atea Pharmaceuticals director Bruno Lucidi has proposed the sale of 6,741 common shares of AVIR, valued at approximately $27,189.82. The shares were acquired through a stock option exercise on November 17, 2026, and the proposed sale date is also November 17, 2026. This notice was filed as a Form 144 with the SEC.

Director Bruce Polsky proposes selling 14,254 Atea Pharmaceuticals (AVIR) shares.

https://www.stocktitan.net/sec-filings/AVIR/144-atea-pharmaceuticals-inc-sec-filing-c29208076665.html
Bruce Polsky, a director at Atea Pharmaceuticals, Inc. (AVIR), has reported a proposed sale of 14,254 common shares, valued at an aggregate market value of $60,840.35, with an approximate sale date of November 16, 2026. These shares were acquired through a stock option exercise on the same date. The filing, a Form 144, indicates a neutral sentiment and impact.

Weekly Recap: C-BEYOND meets endpoint and Atea receives $65 million

https://www.tradingview.com/news/tradingview:b739ea5958b3c:0-weekly-recap-c-beyond-meets-endpoint-and-atea-receives-65-million/
Atea Pharmaceuticals (NASDAQ:AVIR) announced that its Phase 3 C-BEYOND trial successfully met its primary endpoint, showing a 94% sustained viral response. The company also secured $65 million from a credit facility, with potential for an additional $135 million, and provided an update on its AT-587 Phase 1 trial. C-FORWARD results are anticipated in early 2027.

Atea Pharmaceuticals (AVIR) Stock Price, Chart & Analysis

https://www.debelegger.nl/en/stock/AVIR.US
This article provides a detailed analysis of Atea Pharmaceuticals (AVIR) stock, including its latest price ($4.22), market capitalization ($336.86M), and key financial figures such as revenue growth (+295.2% last quarter). It also covers analyst expectations, a "Belegger score" of 32 out of 100, and various valuation metrics, concluding with hypothetical future price scenarios and upcoming quarterly figures.

Atea Pharmaceuticals Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63075370/atea-pharmaceuticals-q3-2026-earnings-call-transcript
Atea Pharmaceuticals announced strong financial health with $191.2 million in cash and a new $200 million credit facility, supporting future commercialization. Their Phase 3 trial for HCV in North America met primary and secondary endpoints, with an NDA submission anticipated by mid-2027, targeting peak U.S. net sales over $700 million. Additionally, a Phase 1 clinical trial for AT-587, a potential first-in-class treatment for chronic HEV, has begun, with a proof-of-concept study planned for early 2027.
Advertisement

What Atea Pharmaceuticals (AVIR) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:cb36fdb32094b:0-what-atea-pharmaceuticals-avir-said-on-its-q3-earnings-call/
Atea Pharmaceuticals is targeting a mid-2027 U.S. application for its hepatitis C treatment, bemnifosbuvir and ruzasvir, following positive results from its C-BEYOND trial and expected early 2027 results from the global C-FORWARD trial. The company projects over $700 million in peak annual U.S. net sales and has secured a credit facility of up to $200 million to support its development and commercialization plans, potentially extending its runway through profitability. Additionally, Atea is advancing its hepatitis E treatment, AT-587, with preliminary proof-of-concept results anticipated by year-end 2027.

Form 8K Atea Pharmaceuticals Inc For: 9 November By Investing.com

https://in.investing.com/news/stock-market-news/form-8k-atea-pharmaceuticalsinc-for-9-november-93CH-5691786
This article announces the filing of a Form 8K by Atea Pharmaceuticals Inc. on November 9, 2026. The brief piece from Investing.com provides no further details beyond the headline and the company's stock symbol AVIR.

A hepatitis C treatment met its trial goals. Atea reported a 93.91% rate on the accepted cure measure.

https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-reports-third-quarter-2026-financial-results-d1uj6325c2me.html
Atea Pharmaceuticals (AVIR) reported a narrower third-quarter net loss of $32.162 million and positive topline results from its Phase 3 C-BEYOND trial for hepatitis C treatment, where bemnifosbuvir/ruzasvir (BEM/RZR) demonstrated non-inferiority to Epclusa with a 93.91% sustained virologic response rate. The company also secured a credit facility for up to $200 million from Hercules Capital, with $65 million drawn, and anticipates these resources will fund operations into mid-2028. Additionally, Atea is advancing its hepatitis E program with AT-587 and expects C-FORWARD trial results in early 2027, targeting a US approval application for BEM/RZR by mid-2027.

Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

https://finance.yahoo.com/healthcare/articles/atea-pharmaceuticals-reports-third-quarter-210500846.html
Atea Pharmaceuticals reported its third-quarter 2026 financial results, highlighting positive topline data from its Phase 3 C-BEYOND trial for hepatitis C virus (HCV) treatment and progress in its hepatitis E virus (HEV) program. The company also secured up to $200 million in non-dilutive funding from Hercules Capital, extending its cash runway into mid-2028. Atea anticipates submitting a New Drug Application for BEM/RZR for HCV treatment in mid-2027.

Atea Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

https://www.globenewswire.com/news-release/2026/11/09/3398942/0/en/atea-pharmaceuticals-reports-third-quarter-2026-financial-results-and-provides-business-update.html
Atea Pharmaceuticals announced its third-quarter 2026 financial results, highlighting positive topline data from its Phase 3 C-BEYOND trial for bemnifosbuvir/ruzasvir (BEM/RZR) in Hepatitis C Virus (HCV) and progress in its Hepatitis E Virus (HEV) program. The company also secured up to $200 million in non-dilutive funding from Hercules Capital, extending its cash runway into mid-2028. Atea anticipates submitting a New Drug Application for BEM/RZR in mid-2027 based on expected C-FORWARD trial results in early 2027.
Advertisement

Form 8K Atea Pharmaceuticals Inc For: 9 November By Investing.com

https://uk.investing.com/news/stock-market-news/form-8k-atea-pharmaceuticalsinc-for-9-november-93CH-4968217
This article reports on the filing of a Form 8K by Atea Pharmaceuticals Inc on November 9, 2026. The filing is brief and does not provide additional details within the content. The stock symbol AVIR is mentioned with a 2.32% increase.

After receiving $65 million, Atea expects available funds to cover planned operations into mid-2028.

https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-secures-credit-facility-for-up-to-200-million-kip5d85t79mq.html
Atea Pharmaceuticals secured a credit facility of up to $200 million from Hercules Capital, receiving an initial $65 million to support its antiviral programs. This financing, combined with existing cash, is expected to fund planned operations into mid-2028. The company anticipates key milestones in 2027, including results from a Phase 3 hepatitis C trial and a US marketing application, with a target US launch in 2028 if approved.

Form 8K Atea Pharmaceuticals Inc For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-8k-atea-pharmaceuticalsinc-for-9-november-93CH-4942984
Atea Pharmaceuticals Inc. filed a Form 8K for November 9th. This filing is a standard regulatory announcement, indicating a significant event that shareholders should be aware of. The article provides the title of the filing and mentions Atea Pharmaceuticals Inc.'s stock symbol, AVIR.

Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital

https://www.globenewswire.com/news-release/2026/11/09/3398239/0/en/atea-pharmaceuticals-secures-credit-facility-for-up-to-200-million-from-hercules-capital.html
Atea Pharmaceuticals has secured a credit facility of up to $200 million from Hercules Capital, enhancing its financial flexibility ahead of the potential commercial launch of bemnifosbuvir/ruzasvir (BEM/RZR) for chronic hepatitis C virus (HCV) in the US. The company received an initial $65 million, with additional funding tied to clinical, regulatory, and commercial milestones. This financing is expected to fund Atea's operations into mid-2028 and potentially through profitability, supporting its global Phase 3 HCV program and its hepatitis E virus (HEV) clinical program.

Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital

https://www.globenewswire.com/fr/news-release/2026/11/09/3398239/0/en/atea-pharmaceuticals-secures-credit-facility-for-up-to-200-million-from-hercules-capital.html
Atea Pharmaceuticals has secured a credit facility of up to $200 million from Hercules Capital, enhancing its financial flexibility ahead of the potential 2028 launch of bemnifosbuvir/ruzasvir (BEM/RZR) for chronic hepatitis C virus (HCV) and advancing its hepatitis E virus (HEV) clinical program. The company received $65 million at closing, with additional funding contingent on achieving clinical, regulatory, financing, and commercial milestones. This non-dilutive financing is expected to fund Atea's operations into mid-2028, with potential to extend through profitability if BEM/RZR is successfully commercialized.
Advertisement

Atea Pharmaceuticals to Host Third Quarter 2026 Financial

https://www.globenewswire.com/news-release/2026/11/02/3393724/0/en/atea-pharmaceuticals-to-host-third-quarter-2026-financial-results-and-business-update-conference-call-on-november-9-2026.html
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) announced it will host a conference call and audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET. The call will cover financial results for the third quarter ended September 30, 2026, and provide a business update. Investors can register to access the live call or find an archived webcast on the company's investor relations website.

Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026

https://finance.yahoo.com/healthcare/articles/atea-pharmaceuticals-host-third-quarter-210500113.html
Atea Pharmaceuticals will host a conference call and audio webcast on November 9, 2026, at 4:30 p.m. ET to report its financial results for the third quarter ended September 30, 2026, and provide a business update. Participants can register to access the live call, and an archive of the webcast will be available on the company's investor relations website. Atea Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing oral antiviral therapeutics for serious viral diseases.

Atea Pharmaceuticals to Host Third Quarter 2026 Financial Results and Business Update Conference Call on November 9, 2026

https://ca.finance.yahoo.com/news/atea-pharmaceuticals-host-third-quarter-210500113.html
Atea Pharmaceuticals, Inc. will host a conference call and audio webcast on Monday, November 9, 2026, at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2026, and to provide a business update. Interested participants can register for the live call or access an archived webcast on the company's investor relations website. Atea Pharmaceuticals is a biopharmaceutical company focused on developing oral antiviral therapeutics for serious viral diseases.

A live webcast will carry Atea’s third-quarter results and business update on Nov. 9.

https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-to-host-third-quarter-2026-financial-results-m3ia0qujpy5y.html
Atea Pharmaceuticals (AVIR) has scheduled a live conference call and audio webcast for November 9, 2026, at 4:30 p.m. ET, to report its third-quarter 2026 financial results and provide a business update. The event will cover the quarter ended September 30, 2026, and an archive will be available on the company’s website for at least 90 days. The announcement was initially made on November 2, 2026, via GlobeNewswire.

Atea Pharmaceuticals, Inc. (AVIR) Seasonal returns chart

https://uk.finance.yahoo.com/quote/AVIR/seasonality/
This article provides a seasonal returns chart for Atea Pharmaceuticals, Inc. (AVIR), displaying the average monthly price return from 2020 to 2026. It includes current stock information, showing AVIR's real-time Nasdaq price and after-hours trading data. The page also features navigation to other financial data like news, statistics, historical data, and analyst profiles for the company.
Advertisement

Atea Pharmaceuticals, Inc. Estimates – NASDAQ:AVIR

https://www.tradingview.com/symbols/NASDAQ-AVIR/financials-estimates/
This article provides an overview of Atea Pharmaceuticals, Inc. (NASDAQ: AVIR) financials and analyst estimates available on TradingView. It highlights sections for exploring reported financial data, comparing actual results with estimates, and visualizing trends across income statements, balance sheets, and cash flow statements. The content emphasizes that it is not investment advice and encourages users to conduct their own research.

Atea Pharmaceuticals, Inc. (AVIR) options chain

https://au.finance.yahoo.com/quote/AVIR/options/?date=1799971200&straddle=false&type=all
This article provides detailed options chain data for Atea Pharmaceuticals, Inc. (AVIR), including both call and put options. It lists various contracts with their strike prices, last trade dates, last prices, bid/ask, volume, open interest, and implied volatility. The data is delayed by 15 minutes and reflects trading as of January 15, 2027, 3:19:28 pm GMT-4.

A stake in Atea Pharmaceuticals (AVIR) is no longer held to influence control.

https://www.stocktitan.net/sec-filings/AVIR/schedule-13g-atea-pharmaceuticals-inc-passive-investment-disclosure-5-b32e9aab7bca.html
Tang Capital Management and associated entities have filed a Schedule 13G for their 6.0% stake in Atea Pharmaceuticals (AVIR), reporting beneficial ownership of 4,814,700 shares. The filing indicates that these shares are no longer held with the purpose or effect of changing or influencing control of Atea Pharmaceuticals, aligning with Rule 13d-1(h). This update reflects a change in the investors' intent regarding their significant holding in the company.

AVIR: Atea Pharmaceuticals Inc Latest Stock Price, Analysis, News and Trading Ideas

https://stocktwits.com/symbol/AVIR
This article provides current stock information for Atea Pharmaceuticals Inc (AVIR), including its latest stock price, market capitalization, volume, and upcoming earnings date. It also details the company's focus on antiviral therapeutics and includes recent news headlines and discussions related to AVIR.

Atea CEO to speak at a New York healthcare conference Sept. 15

https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-to-present-at-the-morgan-stanley-24th-annual-qqfp1e6ql9a9.html
Atea Pharmaceuticals (AVIR) announced that its CEO and Founder, Jean-Pierre Sommadossi, along with other management team members, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, in New York. A live webcast of the presentation will be available on the company's investor relations website, with an archived version accessible for at least 90 days. The announcement on September 8, 2026, was followed by a 2.74% drop in AVIR's stock price that day, with a trough of -3.9%.
Advertisement

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

https://finance.yahoo.com/healthcare/articles/atea-pharmaceuticals-present-morgan-stanley-110000630.html
Atea Pharmaceuticals, Inc. announced that its CEO and founder, Jean-Pierre Sommadossi, along with other management team members, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The presentation will be webcast live and archived on the company's website. Atea Pharmaceuticals is a biopharmaceutical company focused on developing oral antiviral therapies for serious viral diseases.

Atea Pharmaceuticals to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

https://www.globenewswire.com/news-release/2026/09/08/3357480/0/en/atea-pharmaceuticals-to-present-at-the-morgan-stanley-24th-annual-global-healthcare-conference.html
Atea Pharmaceuticals announced that its CEO and founder, Jean-Pierre Sommadossi, along with other management team members, will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. The presentation will discuss the company's progress in developing oral antiviral therapeutics for serious viral diseases. A live webcast will be available on the company's website.

Atea Pharmaceuticals (AVIR.US) will release its earnings report after market close on August 12.

https://www.moomoo.com/news/post/74284663/atea-pharmaceuticals-avirus-will-release-its-earnings-report-after-market
Atea Pharmaceuticals (AVIR.US) is scheduled to release its earnings report after the market closes on August 12. This announcement provides investors with the specific date to anticipate the company's financial performance update.

Morgan Stanley Adjusts PT on Atea Pharmaceuticals to $7 From $6, Maintains Equalweight Rating

https://www.marketscreener.com/news/morgan-stanley-adjusts-pt-on-atea-pharmaceuticals-to-7-from-6-maintains-equalweight-rating-ce7859d9dd8afe2c
Morgan Stanley has increased its price target for Atea Pharmaceuticals (AVIR) to $7 from $6, while reiterating an "Equalweight" rating on the stock. This adjustment comes amidst recent company news, including Atea's Q2 2026 earnings call and positive topline results from its C-BEYOND Phase 3 trial for Hepatitis C. The firm's analysis reflects ongoing developments in Atea's pipeline of antiviral therapies.

Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.15 EPS

https://www.marketbeat.com/instant-alerts/atea-pharmaceuticals-nasdaqavir-releases-earnings-results-beats-expectations-by-015-eps-2026-08-12/
Atea Pharmaceuticals (NASDAQ:AVIR) announced its quarterly earnings, reporting an EPS of ($0.41), surpassing the consensus estimate of ($0.56) by $0.15. The company's shares traded at $5.06, and it has a market capitalization of approximately $405 million. Analyst sentiment is divided, with one Strong Buy and one Sell rating, while institutional investors hold a significant portion of the stock.
Advertisement

Atea Pharmaceuticals Reports Q2 2026 Financials and Clinical Progress in Form 10-Q Filing

https://kalkinemedia.com/us/news/announcements/atea-pharmaceuticals-reports-q2-2026-financials-and-clinical-progress-in-form-10-q-filing
Atea Pharmaceuticals has filed its Q2 2026 Form 10-Q report, detailing its financial status, including 80,204,699 shares outstanding as of August 10, 2026. The company is actively pursuing two antiviral programs: the C-FORWARD Phase 3 clinical trial for Hepatitis C (HCV) with BEM/RZR, and clinical trials for AT-587 targeting Hepatitis E (HEV). Atea plans to submit a New Drug Application (NDA) to the FDA for the BEM/RZR regimen for HCV treatment.

ATEA PHARMACEUTICALS ($AVIR) Releases Q2 2026 Earnings

https://www.quiverquant.com/news/ATEA+PHARMACEUTICALS+%28%24AVIR%29+Releases+Q2+2026+Earnings
ATEA Pharmaceuticals ($AVIR) reported its Q2 2026 earnings, posting a loss of -$0.41 per share, significantly beating analyst estimates of -$0.57. The company's revenue matched estimates at $0. The article also details recent hedge fund activity for AVIR, showing institutional investors adding and decreasing shares in their portfolios.

Atea Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

https://www.globenewswire.com/news-release/2026/08/12/3344063/0/en/atea-pharmaceuticals-reports-second-quarter-2026-financial-results-and-provides-business-update.html
Atea Pharmaceuticals announced its second-quarter 2026 financial results, highlighting positive Phase 3 C-BEYOND trial results for BEM/RZR in treating HCV, which met primary and secondary endpoints. The company also provided updates on its C-FORWARD trial, expected in early Q1 2027, and advancements in its AT-587 Phase 1 trial for Hepatitis E Virus. Financially, Atea reported $219.5 million in cash and investments, with decreased R&D and G&A expenses compared to the previous year.

Atea Hepatitis C Regimen Posts 93.9% Sustained Response

https://www.stocktitan.net/news/AVIR/atea-pharmaceuticals-reports-second-quarter-2026-financial-results-fl5hng62fey3.html
Atea Pharmaceuticals reported Q2 2026 financial results, including a net loss of $32.9 million, and provided a business update highlighting progress in its viral hepatitis pipeline. The Phase 3 C-BEYOND trial for its HCV regimen (BEM/RZR) met primary and secondary non-inferiority endpoints with a 93.9% sustained virologic response. The company also announced the completion of enrollment for its C-FORWARD trial and the initiation of a Phase 1 trial for AT-587 for chronic HEV.

Atea Pharmaceuticals Leads Our Trio Of Promising Penny Stocks

https://www.webull.com/news/15351312634553344
This article identifies three promising penny stocks: Atea Pharmaceuticals (AVIR), Mammoth Energy Services (TUSK), and Tilly's (TLYS), highlighting their financial health and growth potential in a rising market. Atea Pharmaceuticals is noted for its strong cash position and positive trial results despite being pre-revenue. Mammoth Energy Services shows improved earnings despite past unprofitability, and Tilly's, while also unprofitable, reported increased sales and reduced net losses.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement